IceCure Revenue Jumps 45% in H1 2026, Cash Position Strengthens to $12M
ICCM sits 75% above its 52-week low of $2.12.
Summary
IceCure Medical reported H1 2026 revenue of $1.8 million, up 45% year-over-year, driven by growth in both ProSense system sales and disposable probes. Gross profit rose to $548,000 from $349,000. The company ended the period with $12.0 million in cash after raising $8.5 million in Q2 financings, providing runway for commercial expansion. The active U.S. commercial install base grew approximately 70%, reflecting increasing physician adoption and procedure volumes. The CHoICE post-marketing study is advancing with additional U.S. clinical sites expected to join, supporting future reimbursement opportunities. This follows the reverse split and Nasdaq compliance regained in June, and the $5.5 million private placement completed earlier in the quarter.
At the time of this announcement, ICCM was trading at $3.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.9M. The 52-week trading range was $2.12 to $42.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.